Vincristine: An Overview

Summary

• ‍BRAND: Oncovin^®, Vincasar^® PFS‍
• DRUG TYPE: Anti-cancer chemotherapy drug‍
• CONDITIONS TREATED: Acute leukemia, Hodgkin's and non- Hodgkin's lymphoma, neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma, Wilms' tumor, multiple myeloma, chronic leukemia, breast cancer, lymphosarcoma, and other cancers in dogs and cats‍
• ADMINISTRATION: Intravenous (IV) injection‍
• CYCLES OF TREATMENT: Usually given once a week or once every 2 weeks.‍
• SIDE EFFECTS: Constipation, low white blood cell count, weakness, and neurological effects‍

What Is Vincristine?

Vincristine is a plant alkaloid derived from the periwinkle plant that is used as a chemotherapy drug. It is classified as a vinca alkaloid and works by preventing cell division, which causes cancer cells to die. Vincristine is one of the oldest chemotherapy drugs and has been used in cancer treatment since the 1960s.

In veterinary medicine, vincristine is commonly used as part of the CHOP protocol for treating canine lymphoma. It can also be used as a single-agent chemotherapy for other types of cancer and is sometimes used to treat immune-mediated thrombocytopenia (low platelet count) in dogs.

How Does Vincristine Work?

Vincristine works by binding to microtubule proteins in cancer cells and preventing them from forming the mitotic spindle, which is necessary for cell division. When the mitotic spindle cannot form, cancer cells are unable to divide and undergo apoptosis (programmed cell death).

Vincristine is most effective against cancer cells that are actively dividing, making it particularly useful against rapidly growing cancers like lymphoma. Because cancer cells divide much more rapidly than most normal cells, vincristine preferentially affects cancer cells while having relatively less impact on normal, slowly-dividing cells. However, some normal cells that do divide rapidly (such as nerve cells) can be affected, which is why neurological side effects can occasionally occur.

Why Is Vincristine Used in the CHOP Protocol?

The CHOP protocol (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) is considered the "gold standard" for treating canine lymphoma. Each drug in the protocol works through a different mechanism, and together they attack the cancer cells from multiple angles, increasing the likelihood of remission.

Vincristine's role in the CHOP protocol is to prevent cell division by disrupting the mitotic spindle. When combined with the other three drugs in the CHOP protocol, each attacking the cancer cells in a different way, the likelihood of achieving remission in canine lymphoma increases significantly.

Dosage and Administration

Vincristine is administered intravenously (into a vein) as an IV injection. The dose is based on the patient's body surface area (BSA), which is calculated from the dog's weight and height. A typical dose ranges from 0.5-0.75 mg/m².

In the CHOP protocol, vincristine is usually given as the third drug in the protocol sequence, given once a week or once every two weeks, depending on the specific protocol being used. The timing and dosage are carefully calculated by your veterinary oncologist to maximize effectiveness while minimizing side effects.

Side Effects and Monitoring

Like all chemotherapy drugs, vincristine can cause side effects. Some of the most common side effects include:

• Constipation: This is the most common side effect of vincristine. The drug can affect nerve function in the gastrointestinal tract, leading to constipation. Your veterinarian may recommend dietary changes or stool softeners to help manage this side effect.
• Low white blood cell count (neutropenia): Vincristine can suppress bone marrow function, leading to decreased white blood cell counts, which increases the risk of infection.
• Weakness and lethargy: Some dogs may experience general weakness or lethargy following treatment.
• Neurological effects: Because vincristine works by affecting nerve cell function, it can occasionally cause neurological side effects such as weakness in the hind legs or peripheral neuropathy, though these are rare in veterinary patients.
• Loss of appetite: Some dogs may experience a decrease in appetite following treatment.

Your veterinary oncologist will monitor your dog closely during treatment with blood work and other diagnostics to watch for these side effects and adjust the treatment plan as needed.

Drug Interactions

Vincristine can interact with other medications. Tell your veterinarian about any other medications your dog is taking, including supplements. Some medications can increase the risk of side effects when combined with vincristine.

Cost

Vincristine is a relatively inexpensive chemotherapy drug compared to some others. The cost can vary depending on your location and your dog's size, but typically ranges from $100 to $300 per dose. Many veterinary oncology practices offer payment plans or financial assistance programs to help manage the cost of treatment.

Conclusion

Vincristine is an important component of the CHOP protocol for treating canine lymphoma. Its unique mechanism of action—preventing cell division by disrupting the mitotic spindle—makes it an effective and essential part of this multi-drug approach. While vincristine does have potential side effects, particularly constipation and neurological effects, these are generally manageable with proper veterinary care and monitoring. When used as part of the CHOP protocol alongside other chemotherapy drugs, vincristine offers dogs with lymphoma a real chance at achieving remission and extending their lifespan.